Desmopressin and oxybutynin in monosymptomatic nocturnal enuresis: a randomized, double-blind, placebo-controlled trial and an assessment of predictive factors

What Was Tested

This randomized controlled trial paper looks at Vasopressin and Desmopressin.

The predictive factors of children with MNE responsive to desmopressin and combination therapy were also evaluated.

Who Took Part

The study group was 206 patients.

By PubMed's age tags, the people studied were children and teenagers, both men and women.

Their sample included 206 patients aged between 6 and 13 (mean age 10.6 ± 2.9 years), 117 males.

All patients were required to have MNE.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Because people in this Vasopressin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the patients and researchers unaware of who received Vasopressin.

Some patients received a placebo instead of Vasopressin, giving a reference point.

As predictive factors, bladder volume and wall thickness index, nocturnal polyuria and voiding latency were considered.

What Was Measured

PubMed files the paper under topics including Antidiuretic Agents, Deamino Arginine Vasopressin, Mandelic Acids and Nocturnal Enuresis.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vasopressin and Desmopressin in 206 patients.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2012 (BJU international), a journal based in England.

More context: the Vasopressin compound page and the Desmopressin compound page, all human trials.